Pet Ct Scanning Services MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy End UserBy ComponentBy Deployment Model
Full title & scope — all 5 axes with their segments
Pet Ct Scanning Services Market Size, Share & Industry Analysis, By Type (Positron Emission Tomography (PET) Scanner, X-ray Computed Tomography (CT) Scanner), By Application (Cardiology, Oncology, Neurology, Other), By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes), By Component (Scanning Services, Equipment Maintenance & Support Services, Software & Data Management Services), By Deployment Model (Fixed/Hospital-based Scanning Centers, Mobile PET-CT Scanning Services), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By TypePositron Emission Tomography · X-ray Computed Tomography
- 02By ApplicationCardiology · Oncology · Neurology
- 03By End UserHospitals · Diagnostic Imaging Centers · Academic & Research Institutes
- 04By ComponentScanning Services · Equipment Maintenance & Support Services · Software & Data Management Services
- 05By Deployment ModelFixed/Hospital-based Scanning Centers · Mobile PET-CT Scanning Services
- 06By Region
Market Analysis & Outlook
PET-CT scanning services combine positron emission tomography and X-ray computed tomography in a single hybrid imaging procedure, most commonly used to stage, monitor and assess treatment response in oncology, alongside cardiology and neurology applications. The category covers the scan procedure itself, delivered through fixed hospital-based imaging suites, standalone diagnostic imaging centers and mobile scanning units, along with the equipment maintenance and software services that support ongoing operation. Buyers are hospital radiology and nuclear medicine departments, independent diagnostic imaging chains, and outsourced imaging service operators that contract scanning capacity to health systems that do not operate their own hybrid scanners.
Growth of 7.98% a year carries the global pet ct scanning services market from USD 2.15 billion in 2025 to USD 4.25 billion in 2034. The full series behind that rate covers USD 1.55 billion in 2020, USD 2.1 billion in 2024, USD 2.3 billion in 2026 and USD 3.12 billion in 2030, with 2025 as the base year.
The type mix shifts over the period. Positron Emission Tomography (PET) Scanner is the largest line in 2025 at USD 1.355 billion, a 63.02% share, moving to USD 2.55 billion and 60% by 2034. X-ray Computed Tomography (CT) Scanner grows fastest at 8.91%, taking its share from 36.98% to 40%, while Positron Emission Tomography (PET) Scanner grows slowest at 7.4%. Share moves toward X-ray Computed Tomography (CT) Scanner and away from Positron Emission Tomography (PET) Scanner, though no line shrinks in revenue terms.
By application, Oncology accounts for 58% of 2025 revenue at USD 1.247 billion, reaching USD 2.338 billion and 55% by 2034. Neurology grows faster at 10.23% against 7.23%, moving from 14% of revenue to 17% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.
Geographically, 42% of 2025 revenue sits in North America (USD 0.903 billion rising to USD 1.573 billion) ahead of Europe at 27% and USD 0.581 billion. Middle East and Africa is smallest, at 4%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.
Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 2.15 billion in 2025 to USD 4.25 billion in 2034, a compound annual rate of 7.98%, having reached USD 2.1 billion in 2024 from USD 1.55 billion in 2020.
- 63.02% of 2025 revenue sits in Positron Emission Tomography (PET) Scanner (USD 1.355 billion) and it remains the largest type line in 2034 at USD 2.55 billion and 60%.
- At 8.91%, X-ray Computed Tomography (CT) Scanner grows faster than any other type line, moving from USD 0.795 billion and 36.98% of revenue in 2025 to USD 1.7 billion and 40% in 2034.
- The bull case puts 2034 revenue at USD 4.675 billion and the bear case at USD 3.825 billion, either side of the USD 4.25 billion base case, each with its own stated assumption in the full report.
- 42% of 2025 revenue is generated in North America, worth USD 0.903 billion and rising to USD 1.573 billion by 2034; Middle East and Africa is smallest at 4%.
- The United States accounts for 80% of North America in the base year, worth USD 0.722 billion in 2025 and reaching USD 1.258 billion by 2034, the worked country example carried through that region's chapters.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By By Type
Base year 2025Positron Emission Tomography (PET) Scanner leads with 63.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
The global pet ct scanning services market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 7.98% rate carrying the total.
The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.
The type mix tilts toward X-ray Computed Tomography (CT) Scanner. The widest spread on the type axis is between X-ray Computed Tomography (CT) Scanner at 8.91% and Positron Emission Tomography (PET) Scanner at 7.4%. X-ray Computed Tomography (CT) Scanner takes its share of revenue from 36.98% to 40% while Positron Emission Tomography (PET) Scanner gives up ground, from 63.02% to 60%. In absolute terms X-ray Computed Tomography (CT) Scanner rises from USD 0.795 billion to USD 1.7 billion, while Positron Emission Tomography (PET) Scanner rises from USD 1.355 billion to USD 2.55 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Asia Pacific and Latin America gain regional share. Asia Pacific moves from 22% of revenue in 2025 to 28% in 2034, worth USD 0.473 billion rising to USD 1.19 billion; Latin America moves from 5% of revenue in 2025 to 6% in 2034, worth USD 0.108 billion rising to USD 0.255 billion. Against that, North America at 42% moving to 37%, Europe at 27% moving to 25%, Middle East and Africa at 4% moving to 4%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
The series never breaks trajectory. Reading the series: USD 1.55 billion in 2020, USD 2.1 billion in 2024, USD 2.15 billion in 2025, USD 2.3 billion in 2026, USD 3.12 billion in 2030 and USD 4.25 billion in 2034. The forecast rate of 7.98% sits against 6.76% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.
Market Growth Factors
X-ray Computed Tomography (CT) Scanner carries the market's growth rate
Market Drivers
3- 01X-ray Computed Tomography (CT) Scanner carries the market's growth rate
8.91% growth in X-ray Computed Tomography (CT) Scanner, against 7.98% for the market as a whole, moves it from USD 0.795 billion and 36.98% of revenue in 2025 to USD 1.7 billion and 40% in 2034. The market's overall 7.98% depends on that rate holding: at the 7.4% recorded by Positron Emission Tomography (PET) Scanner, the same revenue base would compound to a materially smaller 2034 total. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02The two largest regions hold most of the base
The largest regional base is North America: USD 0.903 billion in 2025 at 42% of the global total, USD 1.573 billion by 2034, still 37%. Europe is next at 27% of revenue, USD 0.581 billion in 2025 and USD 1.063 billion in 2034. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03The base has grown every year since 2020
USD 1.55 billion in 2020, USD 2.1 billion in 2024 and USD 2.15 billion in 2025: 6.76% compound growth before the forecast period even begins. The forecast period then runs at 7.98%, ending 2034 at USD 4.25 billion. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7.98% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising cancer incidence and oncology imaging demand | High | +0.95 | High | High | High |
| 2 | Expanding hybrid scanner installed base and hospital capital investment | High | +0.55 | High | Medium | Medium |
| 3 | Growth of outsourced and mobile scanning service models | Medium-High | +0.38 | Medium | High | High |
| 4 | Radiopharmaceutical tracer advances and reimbursement expansion | Medium | +0.3 | Medium | Medium | Medium |
| 5 | Adoption of AI-based image reconstruction and workflow software | Medium | +0.22 | Low | Medium | High |
| 6 | Others | Low | +0.15 | Low | Low | Low |
| Total | +2.55 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High capital and operating cost limiting adoption in price-sensitive markets | Medium | −0.2 | Medium | Medium | Low |
| 2 | Limited reimbursement coverage and radiation-exposure caution in emerging markets | Medium | −0.15 | Medium | Medium | Medium |
| 3 | Shortage of trained nuclear medicine specialists and technologists | Low | −0.1 | Low | Medium | Medium |
| Total | −0.45 | |||||
Drivers contribute 2.55 Billion and restraints remove 0.45 Billion, a net 2.1 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 7.98% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Positron Emission Tomography (PET) Scanner grows below the market rate
Market Restraints
2- 01Positron Emission Tomography (PET) Scanner grows below the market rate
With 63.02% of 2025 revenue (USD 1.355 billion) Positron Emission Tomography (PET) Scanner is where most of the market sits, and it grows at only 7.4% against the market's 7.98%. Revenue still reaches USD 2.55 billion by 2034 and share still falls to 60%: a drag on the average rather than a decline.
- 02Middle East and Africa stays the smallest region throughout
Middle East and Africa accounts for 4% of 2025 revenue at USD 0.086 billion, reaching USD 0.17 billion and 4% by 2034, the smallest of the five regions in both years. Its absolute contribution to the revenue added by 2034 stays limited whatever its own growth rate does.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
A bull case of USD 4.675 billion by 2034, against USD 4.25 billion in the base case, turns on a single stated assumption: bull case assumes faster-than-expected hybrid scanner replacement cycles and broader reimbursement expansion for oncology PET-CT in markets outside the United States, Germany and Japan. The USD 2.15 billion 2025 base is common to both.
- 02X-ray Computed Tomography (CT) Scanner share moves from 36.98% to 40%
X-ray Computed Tomography (CT) Scanner grows at 8.91% against 7.98% for the market, adding revenue from USD 0.795 billion in 2025 to USD 1.7 billion in 2034 and taking its share from 36.98% to 40%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Positron Emission Tomography (PET) Scanner.
Market Challenges
Revenue is concentrated in Positron Emission Tomography (PET) Scanner
Market Challenges
2- 01Revenue is concentrated in Positron Emission Tomography (PET) Scanner
With 63.02% of 2025 revenue and 60% of 2034 revenue (USD 1.355 billion rising to USD 2.55 billion) Positron Emission Tomography (PET) Scanner is where the market's exposure sits. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02The United States is 80% of North America
80% of the leading region is one country: the United States, at USD 0.722 billion against North America's USD 0.903 billion in 2025, and USD 1.258 billion by 2034. Regional totals therefore move largely with one country's demand, so a regional forecast is more exposed to single-country conditions than its size alone suggests.
Segmentation Analysis
5 axesThe market is divided by type and by application, end user, component and deployment model; five axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
All two type lines expand in revenue terms over the forecast period. Share is the dividing line; one takes it, the other cedes it.
By Type · 2 segments
X-ray Computed Tomography (CT) Scanner Outpaces the Axis While Positron Emission Tomography (PET) Scanner Holds the Largest Share
- Largest Positron Emission Tomography (PET) Scanner · 63%
- Fastest X-ray Computed Tomography (CT) Scanner · 8.9%
- Moves most Positron Emission Tomography (PET) Scanner · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Positron Emission Tomography (PET) Scanner | $1.35B | 63% | $2.55B | 60%-3 | 7.4% |
| X-ray Computed Tomography (CT) Scanner | $0.80B | 37% | $1.70B | 40%+3 | 8.9% |
Positron emission tomography (PET) scanner components lead because PET's tracer-based functional imaging is the diagnostic capability that justifies the hybrid procedure's premium price, particularly for oncology staging. X-ray computed tomography (CT) scanner components grow fastest as providers upgrade to higher-resolution CT modules for attenuation correction and increasingly bill standalone diagnostic CT alongside the same visit. By 2034 Positron Emission Tomography (PET) Scanner is still ahead, making this a shift in weight rather than a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Application · 4 segments
Neurology Outpaces the Axis While Oncology Holds the Largest Share
- Largest Oncology · 58%
- Fastest Neurology · 10.2%
- Moves most Oncology · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Cardiology | $0.43B | 20% | $0.85B | 20% | 7.9% |
| Oncology | $1.25B | 58% | $2.34B | 55%-3 | 7.2% |
| Neurology | $0.30B | 14% | $0.72B | 17%+3 | 10.2% |
| Other | $0.17B | 8% | $0.34B | 8% | 7.9% |
Oncology leads because PET-CT's primary clinical value lies in cancer staging, restaging and treatment-response monitoring, where hybrid imaging outperforms single-modality alternatives. Neurology is the fastest-growing application as expanding use of amyloid and tau-targeted tracers broadens PET-CT's role in diagnosing neurodegenerative disease earlier in its course. Oncology remains the largest line through 2034, so the axis changes in proportion rather than in order.
By End User · 3 segments
Scale in Hospitals and Growth in Academic & Research Institutes Define the End user Axis
- Largest Hospitals · 52%
- Fastest Academic & Research Institutes · 9%
- Moves most Hospitals · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $1.12B | 52% | $2.04B | 48%-4 | 6.9% |
| Diagnostic Imaging Centers | $0.82B | 38% | $1.74B | 41%+3 | 8.8% |
| Academic & Research Institutes | $0.21B | 10% | $0.47B | 11%+1 | 9% |
Hospitals lead because complex oncology and cardiology cases are concentrated where multidisciplinary care teams and inpatient support already exist. Diagnostic imaging centers grow fastest as health systems shift routine and follow-up scanning to lower-cost, centralized outpatient sites to expand appointment capacity and shorten referral wait times. Hospitals remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Component · 3 segments
Software & Data Management Services Outpaces the Axis While Scanning Services Holds the Largest Share
- Largest Scanning Services · 74%
- Fastest Software & Data Management Services · 12.8%
- Moves most Scanning Services · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Scanning Services | $1.59B | 74% | $2.98B | 70%-4 | 7.2% |
| Equipment Maintenance & Support Services | $0.39B | 18% | $0.77B | 18% | 7.9% |
| Software & Data Management Services | $0.17B | 8% | $0.51B | 12%+4 | 12.8% |
Scanning services lead because procedure volume is the direct revenue driver in a services-oriented market; every scan performed carries its own fee regardless of which component supports it. Software and data management is the fastest-growing component as providers adopt AI-assisted reconstruction and centralized reporting to manage rising scan throughput without proportionally expanding staff. By 2034 Scanning Services is still ahead, making this a shift in weight rather than a change of leader.
By Deployment Model · 2 segments
Mobile PET-CT Scanning Services Outpaces the Axis While Fixed/Hospital-based Scanning Centers Holds the Largest Share
- Largest Fixed/Hospital-based Scanning Centers · 82%
- Fastest Mobile PET-CT Scanning Services · 10.8%
- Moves most Fixed/Hospital-based Scanning Centers · -5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Fixed/Hospital-based Scanning Centers | $1.76B | 82% | $3.27B | 77%-5 | 7.1% |
| Mobile PET-CT Scanning Services | $0.39B | 18% | $0.98B | 23%+5 | 10.8% |
Fixed, hospital-based centers lead because the high capital cost of hybrid scanners favors permanent installation where referral volume is already concentrated. Mobile scanning services grow fastest as operators extend coverage to rural and secondary markets where procedure demand does not yet justify a dedicated on-site scanner. Fixed/Hospital-based Scanning Centers remains the largest line through 2034, so the axis changes in proportion rather than in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 5 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 42%
- By 2034 37%
- Revenue $0.90B → $1.57B
North America holds 42% of the global pet ct scanning services market in 2025, worth USD 0.903 billion rising to USD 1.573 billion in 2034. It is a dominant region on this axis, first by revenue throughout the period.
By 2034 the share stands at 37%, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Positron Emission Tomography (PET) Scanner leads here as it does globally, at 63.02% of 2025 revenue, and X-ray Computed Tomography (CT) Scanner again grows fastest at 8.91%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 80% of it, growing 1.7×.
- In region 1 of 2
- Of region 80%
- Of global 33.6%
- Revenue $0.72B → $1.26B
80% of North America's base-year revenue comes from the United States; USD 0.722 billion, rising to USD 1.258 billion by 2034. At 80% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 0.903 billion in 2025 and USD 1.573 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The type pattern in the United States is the global one: 63.02% of 2025 revenue in Positron Emission Tomography (PET) Scanner, 60% by 2034, against 8.91% growth in X-ray Computed Tomography (CT) Scanner taking it from 36.98% to 40%. Because the country carries 80% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by type for the United States is reported separately in the full report.
In the United States, veterinary CT scanning sits at the intersection of state-level veterinary practice law and federal radiation-safety oversight. The scanners themselves are treated by the Food and Drug Administration as radiation-emitting electronic products under its radiation control provisions, meaning manufacturers must meet applicable performance and safety standards regardless of whether the equipment is destined for human or animal use. Delivery of the scanning service, by contrast, falls to state veterinary medical boards, which license the practicing veterinarians and, in many states, the facility itself, while state radiation health agencies separately require registration of the equipment and adequate shielding, operator training, and safety protocols before a clinic may operate a scanner on patients.
Competition in the United States runs between the suppliers this study tracks: General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet. Positron Emission Tomography (PET) Scanner, at 63.02% of 2025 revenue, is where the volume sits, and X-ray Computed Tomography (CT) Scanner, growing at 8.91%, is where position changes hands over the forecast period. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 20%
- Of global 8.4%
- Revenue $0.18B → $0.32B
Within North America, Canada accounts for 20% of regional revenue and 8.42% of the global total, worth USD 0.181 billion in 2025 and USD 0.315 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25%
- Revenue $0.58B → $1.06B
Europe holds 27% of the global pet ct scanning services market in 2025, worth USD 0.581 billion with USD 1.063 billion projected for 2034. It is a leading region on this axis, second by revenue throughout the period.
Its share moves to 25% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
Within the region the type split tracks the global one; 63.02% of 2025 revenue in Positron Emission Tomography (PET) Scanner, fastest growth of 8.91% in X-ray Computed Tomography (CT) Scanner. Revenue for Europe is broken out by every segmentation axis and by country in the full report.
Germany
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 30%
- Of global 8.1%
- Revenue $0.17B → $0.32B
30% of Europe's base-year revenue comes from Germany; USD 0.174 billion, rising to USD 0.319 billion by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 0.581 billion in 2025 and USD 1.063 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Germany follows the type mix reported at global level: Positron Emission Tomography (PET) Scanner is the largest line at 63.02% of 2025 revenue, moving to 60% by 2034, while X-ray Computed Tomography (CT) Scanner grows fastest at 8.91% and takes its share from 36.98% to 40%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Germany by type separately.
In Germany, the delivery of pet CT scanning services is governed primarily by the federal veterinary professional framework, which restricts diagnostic imaging to licensed veterinarians operating under recognized practice standards, and by the national radiation protection regime, which treats CT as an ionizing-radiation modality requiring a specific licence to operate rather than simple equipment registration. Operators and staff must hold demonstrated expertise recognized under this radiation protection law before a facility may run a scanner on animals, and imaging equipment must be installed, shielded, and maintained to the technical standards set out under that same regime. General EU medical device rules for human diagnostic equipment do not extend to veterinary-only use of such scanners.
Competition in Germany runs between the suppliers this study tracks: General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet. The commercially relevant division is 63.02% of 2025 revenue in Positron Emission Tomography (PET) Scanner, where the volume is, against 8.91% growth in X-ray Computed Tomography (CT) Scanner, where share moves.
United Kingdom
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 25%
- Of global 6.7%
- Revenue $0.14B → $0.27B
The United Kingdom is sized at USD 0.145 billion in 2025, rising to USD 0.266 billion by 2034; 6.74% of global revenue and 25% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 18%
- Of global 4.9%
- Revenue $0.10B → $0.19B
France is sized at USD 0.105 billion in 2025, rising to USD 0.191 billion by 2034; 4.88% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 6 points of share by 2034, while revenue still grows 2.5×.
- Rank 3 of 5
- 2025 share 22%
- By 2034 28%
- Revenue $0.47B → $1.19B
In Asia Pacific, 22% of global revenue puts 2025 at USD 0.473 billion with USD 1.19 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share has moved up to 28%, at a pace above the 7.98% global rate, which is what makes this region worth reading separately rather than scaling from the total.
Positron Emission Tomography (PET) Scanner leads here as it does globally, at 63.02% of 2025 revenue, and X-ray Computed Tomography (CT) Scanner again grows fastest at 8.91%. Per-axis and per-country detail for Asia Pacific sits in the full report.
Japan
The largest market in Asia Pacific, growing 2.0×.
- In region 1 of 3
- Of region 35%
- Of global 7.7%
- Revenue $0.17B → $0.33B
The largest single market in Asia Pacific is Japan, at USD 0.166 billion in 2025 and USD 0.333 billion in 2034. At 35% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Set against USD 0.473 billion and USD 1.19 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Demand in Japan follows the type mix reported at global level: Positron Emission Tomography (PET) Scanner is the largest line at 63.02% of 2025 revenue, moving to 60% by 2034, while X-ray Computed Tomography (CT) Scanner grows fastest at 8.91% and takes its share from 36.98% to 40%. With 35% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Japan is reported separately in the full report.
In Japan, veterinary CT scanning services are shaped by the Veterinarians Act, which limits the practice of animal diagnostic imaging to licensed veterinarians and veterinary facilities registered with the relevant prefectural authority, under the oversight of the Ministry of Agriculture, Forestry and Fisheries. Because CT equipment emits ionizing radiation, its installation and use in a veterinary setting also falls under national laws addressing radiation hazard prevention, which impose facility shielding requirements, equipment inspection, and operator safety training distinct from the human-medical radiological framework. Suppliers of imaging equipment to veterinary clinics must ensure the hardware meets applicable electrical and radiation-safety product standards before it can be installed and operated commercially.
Competition in Japan runs between the suppliers this study tracks: General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet. Two different problems sit on the same axis: holding Positron Emission Tomography (PET) Scanner at 63.02% of 2025 revenue, and taking X-ray Computed Tomography (CT) Scanner while it grows at 8.91%.
China
2nd-largest in Asia Pacific, growing 2.9×.
- In region 2 of 3
- Of region 30%
- Of global 6.6%
- Revenue $0.14B → $0.42B
China is sized at USD 0.142 billion in 2025, rising to USD 0.417 billion by 2034; 6.6% of global revenue and 30% of Asia Pacific. It is reported separately from Japan across every segmentation axis in the full report.
India
3rd-largest in Asia Pacific, growing 3.0×.
- In region 3 of 3
- Of region 15%
- Of global 3.3%
- Revenue $0.07B → $0.21B
Within Asia Pacific, India accounts for 15% of regional revenue and 3.3% of the global total, worth USD 0.071 billion in 2025 and USD 0.214 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 2.4×.
- Rank 4 of 5
- 2025 share 5%
- By 2034 6%
- Revenue $0.11B → $0.26B
5% of the global pet ct scanning services market sits in Latin America in 2025, worth USD 0.108 billion with USD 0.255 billion projected for 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
By 2034 the share has moved up to 6%, because it outgrows the market's 7.98%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: Positron Emission Tomography (PET) Scanner largest at 63.02% of 2025 revenue, X-ray Computed Tomography (CT) Scanner fastest at 8.91%. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.4×.
- In region 1 of 2
- Of region 54.6%
- Of global 2.7%
- Revenue $0.06B → $0.14B
54.6% of Latin America's base-year revenue comes from Brazil; USD 0.059 billion, rising to USD 0.14 billion by 2034. At 54.6% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.108 billion and USD 0.255 billion for the region, it is why this market rather than a smaller one is the one reported in full.
Brazil buys along the same lines as the market globally; Positron Emission Tomography (PET) Scanner first at 63.02% of 2025 revenue and 60% in 2034, X-ray Computed Tomography (CT) Scanner fastest at 8.91% on a share moving from 36.98% to 40%. Since 54.6% of Latin America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Brazil carries its own type breakdown in the full report.
In Brazil, the practice of veterinary medicine, including diagnostic imaging such as CT scanning of companion animals, is overseen by the Federal Council of Veterinary Medicine together with the regional veterinary councils, which license practitioners and accredit the clinics offering such services. Because CT equipment is a source of ionizing radiation, its installation and operation are additionally subject to national nuclear-safety oversight, which requires facility licensing, shielding assessment, and periodic inspection of the equipment separate from veterinary licensure itself. Suppliers placing imaging equipment into the Brazilian market must also satisfy applicable national health-surveillance requirements governing electromedical equipment safety and quality before commercial installation.
In Brazil the field is General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet. Two different problems sit on the same axis: holding Positron Emission Tomography (PET) Scanner at 63.02% of 2025 revenue, and taking X-ray Computed Tomography (CT) Scanner while it grows at 8.91%.
Mexico
2nd-largest in Latin America, growing 2.4×.
- In region 2 of 2
- Of region 29.6%
- Of global 1.5%
- Revenue $0.03B → $0.08B
Mexico is sized at USD 0.032 billion in 2025, rising to USD 0.077 billion by 2034; 1.49% of global revenue and 29.6% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 5 of 5
- 2025 share 4%
- By 2034 4%
- Revenue $0.09B → $0.17B
Middle East and Africa holds 4% of the global pet ct scanning services market in 2025, worth USD 0.086 billion rising to USD 0.17 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
4% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The type mix reported at global level applies here, with Positron Emission Tomography (PET) Scanner the largest line at 63.02% of 2025 revenue and X-ray Computed Tomography (CT) Scanner the fastest-growing at 8.91%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.0×.
- In region 1 of 2
- Of region 45.3%
- Of global 1.8%
- Revenue $0.04B → $0.08B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.039 billion in 2025 and USD 0.077 billion in 2034. It accounts for 45.3% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.086 billion in 2025 and USD 0.17 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The type pattern in Saudi Arabia is the global one: 63.02% of 2025 revenue in Positron Emission Tomography (PET) Scanner, 60% by 2034, against 8.91% growth in X-ray Computed Tomography (CT) Scanner taking it from 36.98% to 40%. Since 45.3% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Saudi Arabia by type separately.
In Saudi Arabia, medical imaging equipment, including CT scanners intended for veterinary use, falls under the registration and market-authorization authority of the Saudi Food and Drug Authority, which requires suppliers to register the device and demonstrate conformity with recognized international safety and quality standards before it may be imported or placed into service. The practice of veterinary medicine and the licensing of veterinary clinics and practitioners is separately overseen by the ministry responsible for agriculture and animal resources, which sets facility and staffing requirements for diagnostic services offered to animal patients. Radiation-emitting equipment such as CT scanners is additionally subject to national nuclear and radiological safety oversight governing installation, shielding, and operator qualification.
General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet are the suppliers covered in Saudi Arabia. The commercially relevant division is 63.02% of 2025 revenue in Positron Emission Tomography (PET) Scanner, where the volume is, against 8.91% growth in X-ray Computed Tomography (CT) Scanner, where share moves.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 30.2%
- Of global 1.2%
- Revenue $0.03B → $0.05B
1.21% of global revenue is generated in the United Arab Emirates; USD 0.026 billion in 2025, reaching USD 0.051 billion in 2034, and 30.2% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, End User, Component, Deployment Model, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Positron Emission Tomography (PET) Scanner and Growth in X-ray Computed Tomography (CT) Scanner Set the Terms of Competition
The field covered here is General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical and RadNet.
The competitive line that matters is the type one, not the geographic one. Volume sits in Positron Emission Tomography (PET) Scanner, USD 1.355 billion and 63.02% of 2025 revenue, 60% by 2034, which is also where an incumbent is hardest to dislodge. The line that changes hands is X-ray Computed Tomography (CT) Scanner at 8.91%, well ahead of Positron Emission Tomography (PET) Scanner at 7.4%. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 2.15 billion.
Manufacturing scale and regulatory clearance experience separate the largest suppliers: GE HealthCare, Siemens Healthineers and Koninklijke Philips hold broad hybrid-scanner clearance portfolios and global service networks that support long-term maintenance contract retention, the recurring revenue base smaller rivals struggle to match. Canon Medical Systems (Toshiba) and Hitachi compete on established installed bases in Japan and adjacent Asian markets. Regional and mobile-service operators such as Alliance HealthCare Services, Shared Imaging and Alliance Medical compete instead on flexible deployment, extending scanning access into markets that cannot justify a permanent installation, while smaller manufacturers like Mediso and Positron Corporation compete on price and niche configuration rather than global reach.
The regional picture sets the entry cost: 42% of revenue is in North America and 27% in Europe, so a credible global position requires both, while Middle East and Africa at 4% can be served opportunistically.
Company-level profiles, financials, shares and development histories are part of the full report rather than this summary.
List of Key Pet Ct Scanning Services Market Companies Profiled
13 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- General Electric (GE HealthCare)(United States)
- Toshiba (Canon Medical Systems)(Japan)
- Koninklijke Philips(Netherlands)
- Siemens Healthineers(Germany)
- Hitachi(Japan)
- Positron Corporation(United States)
- Mediso(Hungary)
- Yangzhou Kindsway Biotech(China)
- United Imaging Healthcare(China)
- Alliance HealthCare Services(United States)
- Shared Imaging(United States)
- Alliance Medical(United Kingdom)
- RadNet(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, End User, Component, Deployment Model), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 13 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Pet Ct Scanning Services Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Pet Ct Scanning Services Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Pet Ct Scanning Services Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Pet Ct Scanning Services Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Pet Ct Scanning Services Market Overview, By Component, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Pet Ct Scanning Services Market Overview, By Deployment Model, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Pet Ct Scanning Services Market Size — Segment Comparison
Chapter 22.Global Pet Ct Scanning Services Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Pet Ct Scanning Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Pet Ct Scanning Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Pet Ct Scanning Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Pet Ct Scanning Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Pet Ct Scanning Services Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
2- 01Positron Emission Tomography (PET) Scanner
- 02X-ray Computed Tomography (CT) Scanner
By Application
4- 01Cardiology
- 02Oncology
- 03Neurology
- 04Other
By End User
3- 01Hospitals
- 02Diagnostic Imaging Centers
- 03Academic & Research Institutes
By Component
3- 01Scanning Services
- 02Equipment Maintenance & Support Services
- 03Software & Data Management Services
By Deployment Model
2- 01Fixed/Hospital-based Scanning Centers
- 02Mobile PET-CT Scanning Services
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from procedure volumes: annual PET-CT scan counts across hospitals, diagnostic imaging centers and mobile units, drawn from national reimbursement claims data (CMS HCPCS codes for PET and PET-CT procedures in the United States, NHS England diagnostic imaging activity statistics) and realized average price per scan taken from published payer fee schedules and self-pay rates. Installed hybrid scanner counts are estimated from OEM shipment disclosures and national radiology equipment registries, then multiplied by average annual utilization and service attach rates for maintenance and software. This bottom-up total is checked against disclosed imaging-segment revenue in GE HealthCare, Siemens Healthineers and Koninklijke Philips filings; where the two diverge, the bottom-up utilization or price assumption is the one corrected, not averaged against the disclosed figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target radiology department administrators and imaging center operations managers who set scan volumes and pricing; procurement and biomedical engineering leads who make capital purchase and service contract decisions; nuclear medicine physicians and radiopharmacists who describe tracer availability and referral patterns; and reimbursement specialists at payer organizations. Sampling weights toward the United States, Germany, Japan and China, the four markets with the deepest installed base and the most complete procedure-level reimbursement data, with lighter coverage across the Middle East and Latin America, where scanning capacity concentrates in a small number of urban centers.
Desk research draws on CMS Hospital Outpatient Prospective Payment System rate schedules and HCPCS utilization data for PET and PET-CT procedures, FDA 510(k) clearance listings for hybrid PET-CT systems, NHS England diagnostic imaging activity statistics, Japan's MHLW reimbursement fee schedule for nuclear medicine, and IAEA radioisotope production and licensing records that bound radiopharmaceutical supply. Company-level detail comes from GE HealthCare, Siemens Healthineers, Koninklijke Philips and Canon Medical Systems annual reports, cross-checked against national radiology equipment registries reporting installed hybrid scanner counts.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected procedure volume growth tied to rising cancer incidence and screening guideline expansion, the pace of hybrid scanner installations replacing older standalone systems, and gradual reimbursement code expansion in markets that currently under-cover PET-CT relative to the United States. Pricing is held roughly flat in real terms in mature markets and modeled to decline modestly per scan as utilization scales in emerging markets. The 2020-2021 procedure volume dip from deferred elective and diagnostic imaging is treated as a temporary disruption and normalized out of the underlying trend. For the forecast to hold, oncology referral volumes must keep growing in line with cancer incidence trends and no major reimbursement rollback should occur in the largest markets.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Historical 2020-2024 figures are back-tested against recorded procedure volume growth reported in national diagnostic imaging statistics and against year-on-year revenue growth disclosed by the largest scanner manufacturers, confirming the bottom-up build tracks reported trends rather than a smoothed approximation. Segment share shifts, particularly the move toward mobile and outsourced scanning models, were reviewed against operating data from mobile imaging service providers. Sensitivities were tested on scanner utilization rate and average price per scan, the two inputs the total is most sensitive to, confirming the forecast range holds under slower-than-expected utilization growth.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in the United States, Germany and Japan, where procedure-level reimbursement data and disclosed manufacturer revenue both exist and broadly agree. It is thinner in the application split between cardiology, neurology and oncology use outside these three markets, where procedure-level coding is coarser, and in the mobile and outsourced service segment generally, where operating data carries less granularity. A material reimbursement policy change in any anchor market, or a disruption to radiopharmaceutical tracer supply, would be the most likely trigger for a revision.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Pet Ct Scanning Services Market projected to reach?
USD 4.25 Billion by 2034, CAGR 7.98%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Positron Emission Tomography (PET) Scanner is the largest line by Type, at 63.02% of revenue in 2025.
06Who are the key companies profiled?
General Electric (GE HealthCare), Toshiba (Canon Medical Systems), Koninklijke Philips, Siemens Healthineers, Hitachi, Positron Corporation, Mediso, Yangzhou Kindsway Biotech, United Imaging Healthcare, Alliance HealthCare Services, Shared Imaging, Alliance Medical, RadNet. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.